NYSE:MDT
Medtronic plc
A diversified global medical technology giant delivering life-saving solutions in cardiology, diabetes, and mobility with a robust $33.5B revenue base.
Key Metrics
Investment Thesis
Bull Case
With revenue growing to $33.54B in 2025 from $31.23B in 2023, Medtronic shows consistent top-line expansion driven by aging demographics and emerging markets. The significant cash generation of $7.04B combined with a healthy balance sheet of $2.22B cash provides ample capacity for M&A or further dividends, supporting long-term value creation.
Bear Case
Investors should be cautious regarding the company's accumulated other comprehensive loss of -$4.28B and substantial debt repayments alongside financing outflows, which may constrain future strategic flexibility. The non-operating loss of -$327M highlights underlying volatility that could erode the reported net profit of $4.69B if market conditions deteriorate.
About Medtronic plc
Medtronic plc is a global leader in medical technology, serving patients with innovative devices and pharmaceuticals across cardiology, diabetes, neurology, and orthopedics. The company generates revenue through its diverse portfolio of implantable and durable medical products sold worldwide to hospitals and healthcare providers.
Analysis
Management Discussion
Medtronic demonstrated strong operational efficiency with operating profit of $5.96B against $33.54B in revenue, indicating healthy margins despite high cost of revenue at $11.63B. The company generated robust free cash flow of $7.04B, allowing for significant shareholder returns via $3.59B in dividends and $3.23B in share repurchases while funding nearly $1.86B in capital expenditures.
Industry Overview
The global medical device industry is characterized by high barriers to entry due to rigorous regulatory oversight and a need for continuous R&D investment, creating a stable but slow-growth environment dominated by large incumbents. Medtronic operates in this mature sector where incremental revenue growth relies heavily on replacing aging implants and expanding into new therapeutic areas like digital health.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $31.23B | $32.36B | $33.54B |
| Cost of Revenue | $10.72B | $11.22B | $11.63B |
| Gross Profit | $20.51B | $21.15B | $21.91B |
| Operating Expenses | $15.02B | $16.00B | $15.95B |
| Operating Income | $5.49B | $5.14B | $5.96B |
| G&A | $10.41B | $10.74B | $10.85B |
| Stock-Based Comp | $355.0M | $393.0M | $429.0M |
| D&A | $2.70B | $2.65B | $2.86B |
| Depreciation | $999.0M | $954.0M | $1.05B |
| Amortization | $1.70B | $1.69B | $1.81B |
| Other OpEx | $4.61B | $5.27B | $5.10B |
| Non-Operating Income | $-121.0M | $-307.0M | $-327.0M |
| Interest Expense | $636.0M | $719.0M | — |
| Pre-Tax Income | $5.36B | $4.84B | $5.63B |
| Income Tax | $1.58B | $1.13B | $936.0M |
| Continuing Ops | $3.78B | $3.70B | $4.69B |
| Discontinued Ops | $0 | $1.0M | $-1.0M |
| Net Income | $3.78B | $3.71B | $4.69B |
| Minority Interest | $26.0M | $28.0M | $29.0M |
| Net to Common | $3.76B | $3.68B | $4.66B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $21.68B | $21.93B | $23.81B |
| Cash & Equivalents | $1.54B | $1.28B | $2.22B |
| Marketable Securities | $6.42B | $6.72B | $6.75B |
| Accounts Receivable | $6.00B | $6.13B | $6.51B |
| Inventory | $5.29B | $5.22B | $5.48B |
| Other Current Assets | $2.42B | $2.58B | $2.86B |
| Long-Term Assets | $69.27B | $68.05B | $67.87B |
| PP&E (Net) | $5.57B | $6.13B | $6.84B |
| Intangibles | $14.84B | $13.22B | $11.67B |
| Goodwill | $41.42B | $40.99B | $41.74B |
| Operating Leases | $1.04B | $1.01B | $1.10B |
| Other LT Assets | $6.39B | $6.69B | $6.53B |
| Total Assets | $90.95B | $89.98B | $91.68B |
| Current Liabilities | $9.05B | $10.79B | $12.88B |
| Accounts Payable | $2.66B | $2.41B | $2.45B |
| Current Leases | $180.0M | $183.0M | $192.0M |
| Taxes Payable | $840.0M | $1.33B | $1.36B |
| Other Current Liab | $5.37B | $6.87B | $8.88B |
| Long-Term Liabilities | $30.23B | $28.77B | $30.55B |
| LT Operating Leases | $869.0M | $840.0M | $918.0M |
| Other LT Liab | $27.00B | $25.00B | $28.05B |
| Total Liabilities | $39.28B | $39.56B | $43.42B |
| Shareholders' Equity | $51.66B | $50.42B | $48.26B |
| Paid-In Capital | $24.59B | $23.13B | $20.83B |
| Retained Earnings | $30.39B | $30.40B | $31.48B |
| AOCI | $-3.50B | $-3.32B | $-4.28B |
| Total L&E | $90.95B | $89.98B | $91.68B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $3.78B | $3.71B | $4.69B |
| Non-Cash Adjustments | $-104.0M | $1.82B | $881.0M |
| Working Capital Changes | $2.36B | $1.27B | $1.47B |
| Cash from Operations | $6.04B | $6.79B | $7.04B |
| Capital Expenditures | $1.46B | $1.59B | $1.86B |
| Cash from Investing | $-3.49B | $-2.37B | $-1.94B |
| Debt Issuances | $5.41B | $0 | $3.21B |
| Debt Repayments | $6.01B | $0 | $0 |
| Share Buybacks | $645.0M | $2.14B | $3.23B |
| Dividends Paid | $3.62B | $3.67B | $3.59B |
| Cash from Financing | $-4.96B | $-4.45B | $-4.36B |
| FX Effect | $243.0M | $-230.0M | $188.0M |
| Net Change in Cash | $-2.17B | $-259.0M | $934.0M |
| Beginning Cash | $3.71B | $1.54B | $1.28B |
| Ending Cash | $1.54B | $1.28B | $2.22B |
Frequently Asked Questions
How does Medtronic plc make money?
Medtronic's revenue is primarily driven by four core therapeutic areas: Cardiac Rhythm Management (pacemakers/ICDs), Diabetes Care (insulin pumps/sensors), Neurological & Surgical Solutions, and Mobility & Orthopedics, supported by a massive $41.7B goodwill portfolio indicating significant prior acquisitions in these fields.
What are the main risks for MDT?
Regulatory changes or stricter FDA approval processes could delay new product launches; high accounts receivable ($6.51B) relative to payables suggests potential working capital pressure in long sales cycles; foreign exchange fluctuations impacting the $2.22B cash position; and reliance on a complex global supply chain for critical components.
What is MDT's competitive advantage?
Medtronic possesses deep regulatory moats as an FDA-approved manufacturer of critical life-support devices, a highly skilled global R&D workforce driving continuous innovation, and an extensive installed base of millions of active implants that ensure recurring revenue streams.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.